Aprogen Biologics flagged for KRX watchlist risk on sustained low market cap

South Korea's KRX has flagged Aprogen Biologics for potential "administrative issue" designation after its market capitalization stayed below KRW 30 billion for 25 trading days, and could be designated if the shortfall persists for 30 trading days.